A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Eliglustat (Primary)
  • Indications Gaucher's disease type I
  • Focus Registrational; Therapeutic Use
  • Acronyms ENGAGE
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 12 Dec 2017 Results (4.5- year data) from this and one other trial assessing improvements in hemoglobin concentration and platelet count , presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Nov 2017 18-month outcomes of the patients who entered the trial extension (n=39), published in the American Journal of Hematology
    • 01 Apr 2016 Status changed from active, no longer recruiting to completed according to the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top